Envoy Medical, Inc. (COCH)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 150K 300K 450K Q2 '23: 218K Q3 '23: 241K Q4 '23: 316K Q1 '24: 297K Q2 '24: 302K Q3 '24: 278K Q4 '24: 225K Q1 '25: 212K Q2 '25: 222K Q3 '25: 208K Q4 '25: 241K Q1 '26: 234K Q2 '26: 207K Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Gross Profit TTM

-900K -600K -300K 0 300K 600K 900K Q2 '23: -376K Q3 '23: -436K Q4 '23: -444K Q1 '24: -441K Q2 '24: -519K Q3 '24: -541K Q4 '24: -517K Q1 '25: -603K Q2 '25: -582K Q3 '25: -612K Q4 '25: -633K Q1 '26: -727K Q2 '26: -798K Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

-27M -18M -9M 0 9M 18M 27M Q4 '21: -6M Q1 '22: -6.5M Q2 '22: -6.3M Q3 '22: -5.2M Q4 '22: -7.1M Q1 '23: -9.4M Q2 '23: -13M Q3 '23: -14.5M Q4 '23: -18.4M Q1 '24: -19.5M Q2 '24: -19.8M Q3 '24: -21.4M Q4 '24: -19.3M Q1 '25: -19.5M Q2 '25: -19.7M Q3 '25: -20.4M Q4 '25: -22.3M Q1 '26: -23.1M Q2 '26: -23.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-30M -15M 0 15M 30M 45M Q4 '21: -251.6K Q1 '22: -652.2K Q2 '22: -2.3M Q3 '22: -9.2M Q4 '22: -2.1M Q1 '23: -13.5M Q2 '23: -25.6M Q3 '23: -22.7M Q4 '23: -29.9M Q1 '24: -22.9M Q2 '24: -13.5M Q3 '24: -21.1M Q4 '24: -20.8M Q1 '25: -19.5M Q2 '25: -21.3M Q3 '25: -21.8M Q4 '25: -23.8M Q1 '26: -23.1M Q2 '26: -23.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

0 350K 700K 1.1M Q2 '23: 594K Q3 '23: 677K Q4 '23: 760K Q1 '24: 738K Q2 '24: 821K Q3 '24: 819K Q4 '24: 742K Q1 '25: 815K Q2 '25: 804K Q3 '25: 820K Q4 '25: 874K Q1 '26: 961K Q2 '26: 1M Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Operating Cash Flow TTM

-27M -18M -9M 0 9M 18M 27M Q4 '21: -3.2M Q1 '22: -2.8M Q2 '22: -2.8M Q3 '22: -7.3M Q4 '22: -8.8M Q1 '23: -11M Q2 '23: -14.7M Q3 '23: -8.3M Q4 '23: -17.1M Q1 '24: -19.7M Q2 '24: -20.3M Q3 '24: -24M Q4 '24: -17.9M Q1 '25: -16.1M Q2 '25: -15.9M Q3 '25: -17.6M Q4 '25: -18.2M Q1 '26: -20.5M Q2 '26: -21.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-21M -14M -7M 0 7M 14M 21M Q3 '23: -8.5M Q4 '23: -17.2M Q1 '24: -19.9M Q4 '25: -18.4M Q3 '23 Q4 '23 Q1 '24 Q4 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 40M 80M 120M Q3 '22: 10.1M Q1 '23: 10.1M Q2 '23: 10.1M Q3 '23: 11.2M Q1 '24: 18.6M Q2 '24: 18.6M Q3 '24: 18.6M Q1 '25: 21.3M Q2 '25: 21.4M Q3 '25: 21.9M Q1 '26: 68.9M Q2 '26: 104M Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-4.50 -3.00 -1.50 0.00 1.50 3.00 4.50 Q2 '23: -3.88 Q3 '23: -3.62 Q4 '23: -2.57 Q1 '24: -1.67 Q2 '24: -0.65 Q3 '24: -1.17 Q4 '24: -1.49 Q1 '25: -1.37 Q2 '25: -1.40 Q3 '25: -1.36 Q4 '25: -1.22 Q1 '26: -1.01 Q2 '26: -0.76 Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.